Clinical Trial Search

Primary: Prevention Capacity-GTO Efficacy (Intent to Treat) — 63.38; 59.79; 61.37; 58.71 percentage of the highest possible score — p=.58

Primary: Change From Baseline in the Weekly Average of Spontaneous Bowel Movements (SBMs) During Treatment — 1.96; 3.42; 1.44 Number of SBMs/week

Primary: Number of Patients With Pathological Complete Response — 34; 17 participants

Primary: Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL]) — 31.75; 30.99 percentage of time — p=0.7304

Primary: Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Triple Therapy Treatment Arms (A, D, and E) — -0.881; -2.321; -2.020 Log10(IU/mL)

Primary: Change From Baseline in the Average Pain Score (NPRS) for Week 2 — -2.20; -2.24; -1.57; -1.77 units on a scale

Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response

Primary: Overall Response to CVT Chemotherapy. — 1; 5 participants

Primary: Change From Period Baseline in FEV1 (L) AUC(0-24h) — 0.209; 0.165; 0.154; 0.121 Liters

Primary: AUX-I Cmax After Injection 1 — 12.6 ng/mL

Primary: Change From Baseline in Mean Oxygen Consumption (mL/kg/Min) at 6 Weeks — 30.5; 30.5; 31.3; 31.3 mL/kg/min — p=0.73

Primary: Progression-free Survival (PFS) — 7.5; 7.6; 9.2; 7.4 Months — p=0.89

Primary: Percent Change in Tc-94m Sestamibi Body Weight Standardized Uptake Value (SUV) Maximum in Tumor Tissue Before and After Administration of Tariquidar, a P-glycoprotein…

Primary: Determine the Incidence of Complete and Partial Response and the Duration of Response in Patients With Langerhans Cell Histiocytosis (LCH) Treated With Sequential…

Primary: Changes of Neurological Scores for Baseline — -0.158; 0; 2.208; -0.766 units on a scale — p=0.343